Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.

Sternberg CN.

Future Oncol. 2019 May;15(13):1437-1457. doi: 10.2217/fon-2018-0940. Epub 2019 Mar 8.

2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
3.

Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.

Schalken J, Fitzpatrick JM.

BJU Int. 2016 Feb;117(2):215-25. doi: 10.1111/bju.13123. Epub 2015 Jun 6. Review.

4.

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.

van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, de Wit R, van Weerden WM.

Eur Urol. 2015 Jun;67(6):981-985. doi: 10.1016/j.eururo.2014.11.033. Epub 2014 Dec 4.

PMID:
25484141
5.
6.

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.

Clin Cancer Res. 2014 Jun 15;20(12):3198-3210. doi: 10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16. Erratum in: Clin Cancer Res. 2017 Jan 1;23 (1):323.

7.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

9.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
10.

Enzalutamide for patients with metastatic castration-resistant prostate cancer.

Ramadan WH, Kabbara WK, Al Basiouni Al Masri HS.

Onco Targets Ther. 2015 Apr 17;8:871-6. doi: 10.2147/OTT.S80488. eCollection 2015. Review.

11.

Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

Chandrasekar T, Yang JC, Gao AC, Evans CP.

Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02. Review.

12.

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS.

J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25.

PMID:
26811535
13.

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions.

Tucci M, Zichi C, Buttigliero C, Vignani F, Scagliotti GV, Di Maio M.

Onco Targets Ther. 2018 Oct 24;11:7353-7368. doi: 10.2147/OTT.S153764. eCollection 2018. Review.

14.

Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.

Bennett LL, Ingason A.

Ann Pharmacother. 2014 Apr;48(4):530-7. doi: 10.1177/1060028013518899. Epub 2014 Jan 23. Review.

PMID:
24458946
15.
16.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603
17.

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS.

Eur J Cancer. 2014 Jan;50(1):78-84. doi: 10.1016/j.ejca.2013.08.020. Epub 2013 Sep 25.

PMID:
24074764
18.

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer.

Golshayan AR, Antonarakis ES.

Core Evid. 2013;8:27-35. doi: 10.2147/CE.S34747. Epub 2013 Apr 4.

19.

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI.

Eur Urol. 2015 Nov;68(5):795-801. doi: 10.1016/j.eururo.2015.01.026. Epub 2015 Feb 16.

20.

Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ.

Eur Urol. 2015 Jan;67(1):53-60. doi: 10.1016/j.eururo.2014.05.005. Epub 2014 May 29.

Supplemental Content

Support Center